<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805827</url>
  </required_header>
  <id_info>
    <org_study_id>PHG-AMA/GAB-0221/01</org_study_id>
    <nct_id>NCT04805827</nct_id>
  </id_info>
  <brief_title>Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)</brief_title>
  <official_title>Randomized Single Oral Dose, Open-label, Two-way, Two-periods, Un-replicated Crossover, Bioequivalence Study to Compare Nerpentin600 mg Film Coated Tablet (Gabapentin 600 mg) Manufactured by EGPI (Egyptian Group for Pharmaceutical Industry) - Egypt for Aman Pharma, Versus Neurontin 300 mg Hard Gelatin Capsule (Gabapentin 300 mg) a Product of Pfizer Egypt, Under License From: Parke-Davis-Germany, a Company of Pfizer INC., USA, on Healthy Subjects Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharma Guide CRO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharma Guide CRO</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted with the aim to investigate whether any differences concerning the&#xD;
      rate and extent of absorption exist between the test and the reference product, Test product&#xD;
      was Nerpentine 600 mg Film coated Tablet (Aman Pharma) Reference Product was Neurontin 300 mg&#xD;
      Capsule.(Pfizer) The comparative bio availability of the two formulations was evaluated based&#xD;
      in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug&#xD;
      concentrations in blood.&#xD;
&#xD;
      Study was open-label, randomized, crossover, with 02 treatments, 02 sequences and 02 periods,&#xD;
      under fasting conditions. one tablet from test product 600 mg against two capsules ( 2*300 mg&#xD;
      ) reference product.&#xD;
&#xD;
      Study population was 34 subjects , males ,adults between 18-55 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Actual">March 7, 2021</completion_date>
  <primary_completion_date type="Actual">March 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized single oral dose, open-label, two-way, two-periods, UN-replicated crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of drug gabapentin</measure>
    <time_frame>0.0, 0.5, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 36 and 48 hours post dose</time_frame>
    <description>(CMAX) Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of gabapentin</measure>
    <time_frame>0.0, 0.5, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 36 and 48 hours post dose</time_frame>
    <description>AUC (Area under the concentration-time curve)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet contains 600 mg Gabapentin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurontin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsule contains 2*300 = 600 mg Gabapentin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>1 tablet contains 600 mg Gabapentin</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neurontin</intervention_name>
    <description>2 capsule contains 2*300 = 600 mg Gabapentin</description>
    <arm_group_label>Neurontin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and non-pregnant female.&#xD;
&#xD;
          2. Subjects should be between the ages of 18 and 55 years.&#xD;
&#xD;
          3. Subject's weight should be within the normal range, preferably have a Body Mass Index&#xD;
             between 18.5 and 30 kg/m2.&#xD;
&#xD;
          4. Subjects with normal range of vital signs (Blood Pressure, Pulse Rate.&#xD;
&#xD;
          5. Respiratory Rate and Body Temperature).&#xD;
&#xD;
          6. Normal physical examination at screening visit.&#xD;
&#xD;
          7. Ability to communicate adequately with the investigator himself or his&#xD;
             representatives.&#xD;
&#xD;
          8. Ability and agreement to comply with the study requirements.&#xD;
&#xD;
          9. Understanding of the study and agreement to give a written informed consent.&#xD;
&#xD;
         10. The ability of the subjects to understand and comply with the study protocol has to be&#xD;
             assessed&#xD;
&#xD;
         11. Females should not be pregnant or lactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Who have a topic constitution or asthma or known allergy for Gabapentin and/or any&#xD;
             other ingredients of the products.&#xD;
&#xD;
          2. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first&#xD;
             drug administration. Systolic blood pressure less than 100 or more than 140 mm Hg and&#xD;
             Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.&#xD;
&#xD;
          3. Pulse rate less than 60 pulse/minute or more than 100 pulse/minute.&#xD;
&#xD;
          4. History or presence of significant smoking (â‰¥10 cigarettes or consumption of tobacco&#xD;
             products and refusal to restrain from smoking or consumption of tobacco products for&#xD;
             48 hours before dosing until checkout).&#xD;
&#xD;
          5. History of difficulty of donating blood.&#xD;
&#xD;
          6. History of difficulty of swallowing.&#xD;
&#xD;
          7. Any history or presence of clinical relevance of cardiovascular, neurological,&#xD;
             musculoskeletal, hematological, hepatic, gastrointestinal, renal, pulmonary,&#xD;
             endocraniological, metabolism or psychiatric disease, any type of porphyria.&#xD;
&#xD;
          8. Presence or history of malabsorption or any gastrointestinal surgery except&#xD;
             appendectomy or except herniotomy.&#xD;
&#xD;
          9. Participation in a drug research study or donating blood within past 2 months before&#xD;
             screening.&#xD;
&#xD;
         10. Subjects who used any of prescribed systemic or topical medication (including OTC&#xD;
             medication) within 2 weeks before the initiation of the study (except single doses of&#xD;
             analgesics which have no drug interaction with study product).&#xD;
&#xD;
         11. History of allergic response to heparin.&#xD;
&#xD;
         12. Presence or history of malabsorption or any gastrointestinal surgery except&#xD;
             appendectomy or except herniotomy.&#xD;
&#xD;
         13. Subjects who regular consumed of beverages or food containing methylxanthines (e.g.&#xD;
             coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg&#xD;
             methylxanthines per day, and refusal to abstain from consumption of these products for&#xD;
             48 hours before dosing until checkout).&#xD;
&#xD;
         14. Founding Positive in the alcohol test done at the time of check in.&#xD;
&#xD;
         15. Founding positive in the Urine drugs of abuse at time of check in.&#xD;
&#xD;
         16. Intake of depot injectable solutions (including study medications) within 6 months&#xD;
             before start of the study.&#xD;
&#xD;
         17. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before&#xD;
             start of the study.&#xD;
&#xD;
         18. Special diet due to any reason, e.g. vegetarian.&#xD;
&#xD;
         19. Subjects who are not suitable to any of inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharma Guide</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pharma Guide CRO</investigator_affiliation>
    <investigator_full_name>Mostafa Kaboah</investigator_full_name>
    <investigator_title>Clinical department manager</investigator_title>
  </responsible_party>
  <keyword>Pharma Guide</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Neurontin</keyword>
  <keyword>Mostafa Kaboah</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>01-04-2021</ipd_time_frame>
    <ipd_url>https://www.pharmaguide-eg.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

